The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Insulin Lispro Injection Market Research Report 2024
Synopsis
The main component of recombinant insulin lispro injection is insulin lispro, which is a human insulin analog produced by genetic recombination technology. It is produced by exchanging the 28th and 29th amino acids on the insulin B chain. It is suitable for the need for insulin Adult diabetic patients who maintain euglycemic homeostasis
The global Recombinant Insulin Lispro Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Recombinant Insulin Lispro Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Insulin Lispro Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Recombinant Insulin Lispro Injection include GT, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Novo Nordisk, Pfizer, BI, Sanofi, Takeda Pharmaceutical Company and Wanbang Biopharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Recombinant Insulin Lispro Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Insulin Lispro Injection.
Report Scope
The Recombinant Insulin Lispro Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Insulin Lispro Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Insulin Lispro Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GT
Tonghua Dongbao Pharmaceutical
Eli Lilly and Company
Novo Nordisk
Pfizer
BI
Sanofi
Takeda Pharmaceutical Company
Wanbang Biopharmaceuticals
United Laboratories
Segment by Type
1ML
3ML
10ML
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Insulin Lispro Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Insulin Lispro Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The main component of recombinant insulin lispro injection is insulin lispro, which is a human insulin analog produced by genetic recombination technology. It is produced by exchanging the 28th and 29th amino acids on the insulin B chain. It is suitable for the need for insulin Adult diabetic patients who maintain euglycemic homeostasis
The global Recombinant Insulin Lispro Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Recombinant Insulin Lispro Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Insulin Lispro Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Recombinant Insulin Lispro Injection include GT, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Novo Nordisk, Pfizer, BI, Sanofi, Takeda Pharmaceutical Company and Wanbang Biopharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Recombinant Insulin Lispro Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Insulin Lispro Injection.
Report Scope
The Recombinant Insulin Lispro Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Insulin Lispro Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Insulin Lispro Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GT
Tonghua Dongbao Pharmaceutical
Eli Lilly and Company
Novo Nordisk
Pfizer
BI
Sanofi
Takeda Pharmaceutical Company
Wanbang Biopharmaceuticals
United Laboratories
Segment by Type
1ML
3ML
10ML
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Insulin Lispro Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Insulin Lispro Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Recombinant Insulin Lispro Injection Market Overview
1.1 Product Overview and Scope of Recombinant Insulin Lispro Injection
1.2 Recombinant Insulin Lispro Injection Segment by Type
1.2.1 Global Recombinant Insulin Lispro Injection Market Value Comparison by Type (2024-2030)
1.2.2 1ML
1.2.3 3ML
1.2.4 10ML
1.3 Recombinant Insulin Lispro Injection Segment by Application
1.3.1 Global Recombinant Insulin Lispro Injection Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Recombinant Insulin Lispro Injection Market Size Estimates and Forecasts
1.4.1 Global Recombinant Insulin Lispro Injection Revenue 2019-2030
1.4.2 Global Recombinant Insulin Lispro Injection Sales 2019-2030
1.4.3 Global Recombinant Insulin Lispro Injection Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Insulin Lispro Injection Market Competition by Manufacturers
2.1 Global Recombinant Insulin Lispro Injection Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Insulin Lispro Injection Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Insulin Lispro Injection Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Insulin Lispro Injection Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Insulin Lispro Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Insulin Lispro Injection, Product Type & Application
2.7 Recombinant Insulin Lispro Injection Market Competitive Situation and Trends
2.7.1 Recombinant Insulin Lispro Injection Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Insulin Lispro Injection Players Market Share by Revenue
2.7.3 Global Recombinant Insulin Lispro Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Insulin Lispro Injection Retrospective Market Scenario by Region
3.1 Global Recombinant Insulin Lispro Injection Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Insulin Lispro Injection Global Recombinant Insulin Lispro Injection Sales by Region: 2019-2030
3.2.1 Global Recombinant Insulin Lispro Injection Sales by Region: 2019-2024
3.2.2 Global Recombinant Insulin Lispro Injection Sales by Region: 2025-2030
3.3 Global Recombinant Insulin Lispro Injection Global Recombinant Insulin Lispro Injection Revenue by Region: 2019-2030
3.3.1 Global Recombinant Insulin Lispro Injection Revenue by Region: 2019-2024
3.3.2 Global Recombinant Insulin Lispro Injection Revenue by Region: 2025-2030
3.4 North America Recombinant Insulin Lispro Injection Market Facts & Figures by Country
3.4.1 North America Recombinant Insulin Lispro Injection Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Insulin Lispro Injection Sales by Country (2019-2030)
3.4.3 North America Recombinant Insulin Lispro Injection Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Insulin Lispro Injection Market Facts & Figures by Country
3.5.1 Europe Recombinant Insulin Lispro Injection Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Insulin Lispro Injection Sales by Country (2019-2030)
3.5.3 Europe Recombinant Insulin Lispro Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Insulin Lispro Injection Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Insulin Lispro Injection Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Insulin Lispro Injection Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Insulin Lispro Injection Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Recombinant Insulin Lispro Injection Market Facts & Figures by Country
3.7.1 Latin America Recombinant Insulin Lispro Injection Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Insulin Lispro Injection Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Insulin Lispro Injection Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Insulin Lispro Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Insulin Lispro Injection Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Insulin Lispro Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Insulin Lispro Injection Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Insulin Lispro Injection Sales by Type (2019-2030)
4.1.1 Global Recombinant Insulin Lispro Injection Sales by Type (2019-2024)
4.1.2 Global Recombinant Insulin Lispro Injection Sales by Type (2025-2030)
4.1.3 Global Recombinant Insulin Lispro Injection Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Insulin Lispro Injection Revenue by Type (2019-2030)
4.2.1 Global Recombinant Insulin Lispro Injection Revenue by Type (2019-2024)
4.2.2 Global Recombinant Insulin Lispro Injection Revenue by Type (2025-2030)
4.2.3 Global Recombinant Insulin Lispro Injection Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Insulin Lispro Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Insulin Lispro Injection Sales by Application (2019-2030)
5.1.1 Global Recombinant Insulin Lispro Injection Sales by Application (2019-2024)
5.1.2 Global Recombinant Insulin Lispro Injection Sales by Application (2025-2030)
5.1.3 Global Recombinant Insulin Lispro Injection Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Insulin Lispro Injection Revenue by Application (2019-2030)
5.2.1 Global Recombinant Insulin Lispro Injection Revenue by Application (2019-2024)
5.2.2 Global Recombinant Insulin Lispro Injection Revenue by Application (2025-2030)
5.2.3 Global Recombinant Insulin Lispro Injection Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Insulin Lispro Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GT
6.1.1 GT Corporation Information
6.1.2 GT Description and Business Overview
6.1.3 GT Recombinant Insulin Lispro Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GT Recombinant Insulin Lispro Injection Product Portfolio
6.1.5 GT Recent Developments/Updates
6.2 Tonghua Dongbao Pharmaceutical
6.2.1 Tonghua Dongbao Pharmaceutical Corporation Information
6.2.2 Tonghua Dongbao Pharmaceutical Description and Business Overview
6.2.3 Tonghua Dongbao Pharmaceutical Recombinant Insulin Lispro Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Tonghua Dongbao Pharmaceutical Recombinant Insulin Lispro Injection Product Portfolio
6.2.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
6.3 Eli Lilly and Company
6.3.1 Eli Lilly and Company Corporation Information
6.3.2 Eli Lilly and Company Description and Business Overview
6.3.3 Eli Lilly and Company Recombinant Insulin Lispro Injection Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Eli Lilly and Company Recombinant Insulin Lispro Injection Product Portfolio
6.3.5 Eli Lilly and Company Recent Developments/Updates
6.4 Novo Nordisk
6.4.1 Novo Nordisk Corporation Information
6.4.2 Novo Nordisk Description and Business Overview
6.4.3 Novo Nordisk Recombinant Insulin Lispro Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novo Nordisk Recombinant Insulin Lispro Injection Product Portfolio
6.4.5 Novo Nordisk Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Recombinant Insulin Lispro Injection Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Recombinant Insulin Lispro Injection Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 BI
6.6.1 BI Corporation Information
6.6.2 BI Description and Business Overview
6.6.3 BI Recombinant Insulin Lispro Injection Sales, Revenue and Gross Margin (2019-2024)
6.6.4 BI Recombinant Insulin Lispro Injection Product Portfolio
6.6.5 BI Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Recombinant Insulin Lispro Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Recombinant Insulin Lispro Injection Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Takeda Pharmaceutical Company
6.8.1 Takeda Pharmaceutical Company Corporation Information
6.8.2 Takeda Pharmaceutical Company Description and Business Overview
6.8.3 Takeda Pharmaceutical Company Recombinant Insulin Lispro Injection Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Takeda Pharmaceutical Company Recombinant Insulin Lispro Injection Product Portfolio
6.8.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.9 Wanbang Biopharmaceuticals
6.9.1 Wanbang Biopharmaceuticals Corporation Information
6.9.2 Wanbang Biopharmaceuticals Description and Business Overview
6.9.3 Wanbang Biopharmaceuticals Recombinant Insulin Lispro Injection Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Wanbang Biopharmaceuticals Recombinant Insulin Lispro Injection Product Portfolio
6.9.5 Wanbang Biopharmaceuticals Recent Developments/Updates
6.10 United Laboratories
6.10.1 United Laboratories Corporation Information
6.10.2 United Laboratories Description and Business Overview
6.10.3 United Laboratories Recombinant Insulin Lispro Injection Sales, Revenue and Gross Margin (2019-2024)
6.10.4 United Laboratories Recombinant Insulin Lispro Injection Product Portfolio
6.10.5 United Laboratories Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Insulin Lispro Injection Industry Chain Analysis
7.2 Recombinant Insulin Lispro Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Insulin Lispro Injection Production Mode & Process
7.4 Recombinant Insulin Lispro Injection Sales and Marketing
7.4.1 Recombinant Insulin Lispro Injection Sales Channels
7.4.2 Recombinant Insulin Lispro Injection Distributors
7.5 Recombinant Insulin Lispro Injection Customers
8 Recombinant Insulin Lispro Injection Market Dynamics
8.1 Recombinant Insulin Lispro Injection Industry Trends
8.2 Recombinant Insulin Lispro Injection Market Drivers
8.3 Recombinant Insulin Lispro Injection Market Challenges
8.4 Recombinant Insulin Lispro Injection Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Recombinant Insulin Lispro Injection Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Recombinant Insulin Lispro Injection Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Recombinant Insulin Lispro Injection Market Competitive Situation by Manufacturers in 2023
Table 4. Global Recombinant Insulin Lispro Injection Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Recombinant Insulin Lispro Injection Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Recombinant Insulin Lispro Injection Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Recombinant Insulin Lispro Injection Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Recombinant Insulin Lispro Injection Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Recombinant Insulin Lispro Injection, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Recombinant Insulin Lispro Injection, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Recombinant Insulin Lispro Injection, Product Type & Application
Table 12. Global Key Manufacturers of Recombinant Insulin Lispro Injection, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Recombinant Insulin Lispro Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Insulin Lispro Injection as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Recombinant Insulin Lispro Injection Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Recombinant Insulin Lispro Injection Sales by Region (2019-2024) & (K Units)
Table 18. Global Recombinant Insulin Lispro Injection Sales Market Share by Region (2019-2024)
Table 19. Global Recombinant Insulin Lispro Injection Sales by Region (2025-2030) & (K Units)
Table 20. Global Recombinant Insulin Lispro Injection Sales Market Share by Region (2025-2030)
Table 21. Global Recombinant Insulin Lispro Injection Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Recombinant Insulin Lispro Injection Revenue Market Share by Region (2019-2024)
Table 23. Global Recombinant Insulin Lispro Injection Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Recombinant Insulin Lispro Injection Revenue Market Share by Region (2025-2030)
Table 25. North America Recombinant Insulin Lispro Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Recombinant Insulin Lispro Injection Sales by Country (2019-2024) & (K Units)
Table 27. North America Recombinant Insulin Lispro Injection Sales by Country (2025-2030) & (K Units)
Table 28. North America Recombinant Insulin Lispro Injection Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Recombinant Insulin Lispro Injection Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Recombinant Insulin Lispro Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Recombinant Insulin Lispro Injection Sales by Country (2019-2024) & (K Units)
Table 32. Europe Recombinant Insulin Lispro Injection Sales by Country (2025-2030) & (K Units)
Table 33. Europe Recombinant Insulin Lispro Injection Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Recombinant Insulin Lispro Injection Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Recombinant Insulin Lispro Injection Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Recombinant Insulin Lispro Injection Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Recombinant Insulin Lispro Injection Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Recombinant Insulin Lispro Injection Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Recombinant Insulin Lispro Injection Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Recombinant Insulin Lispro Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Recombinant Insulin Lispro Injection Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Recombinant Insulin Lispro Injection Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Recombinant Insulin Lispro Injection Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Recombinant Insulin Lispro Injection Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Recombinant Insulin Lispro Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Recombinant Insulin Lispro Injection Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Recombinant Insulin Lispro Injection Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Recombinant Insulin Lispro Injection Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Recombinant Insulin Lispro Injection Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Recombinant Insulin Lispro Injection Sales (K Units) by Type (2019-2024)
Table 51. Global Recombinant Insulin Lispro Injection Sales (K Units) by Type (2025-2030)
Table 52. Global Recombinant Insulin Lispro Injection Sales Market Share by Type (2019-2024)
Table 53. Global Recombinant Insulin Lispro Injection Sales Market Share by Type (2025-2030)
Table 54. Global Recombinant Insulin Lispro Injection Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Recombinant Insulin Lispro Injection Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Recombinant Insulin Lispro Injection Revenue Market Share by Type (2019-2024)
Table 57. Global Recombinant Insulin Lispro Injection Revenue Market Share by Type (2025-2030)
Table 58. Global Recombinant Insulin Lispro Injection Price (US$/Unit) by Type (2019-2024)
Table 59. Global Recombinant Insulin Lispro Injection Price (US$/Unit) by Type (2025-2030)
Table 60. Global Recombinant Insulin Lispro Injection Sales (K Units) by Application (2019-2024)
Table 61. Global Recombinant Insulin Lispro Injection Sales (K Units) by Application (2025-2030)
Table 62. Global Recombinant Insulin Lispro Injection Sales Market Share by Application (2019-2024)
Table 63. Global Recombinant Insulin Lispro Injection Sales Market Share by Application (2025-2030)
Table 64. Global Recombinant Insulin Lispro Injection Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Recombinant Insulin Lispro Injection Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Recombinant Insulin Lispro Injection Revenue Market Share by Application (2019-2024)
Table 67. Global Recombinant Insulin Lispro Injection Revenue Market Share by Application (2025-2030)
Table 68. Global Recombinant Insulin Lispro Injection Price (US$/Unit) by Application (2019-2024)
Table 69. Global Recombinant Insulin Lispro Injection Price (US$/Unit) by Application (2025-2030)
Table 70. GT Corporation Information
Table 71. GT Description and Business Overview
Table 72. GT Recombinant Insulin Lispro Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. GT Recombinant Insulin Lispro Injection Product
Table 74. GT Recent Developments/Updates
Table 75. Tonghua Dongbao Pharmaceutical Corporation Information
Table 76. Tonghua Dongbao Pharmaceutical Description and Business Overview
Table 77. Tonghua Dongbao Pharmaceutical Recombinant Insulin Lispro Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Tonghua Dongbao Pharmaceutical Recombinant Insulin Lispro Injection Product
Table 79. Tonghua Dongbao Pharmaceutical Recent Developments/Updates
Table 80. Eli Lilly and Company Corporation Information
Table 81. Eli Lilly and Company Description and Business Overview
Table 82. Eli Lilly and Company Recombinant Insulin Lispro Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Eli Lilly and Company Recombinant Insulin Lispro Injection Product
Table 84. Eli Lilly and Company Recent Developments/Updates
Table 85. Novo Nordisk Corporation Information
Table 86. Novo Nordisk Description and Business Overview
Table 87. Novo Nordisk Recombinant Insulin Lispro Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Novo Nordisk Recombinant Insulin Lispro Injection Product
Table 89. Novo Nordisk Recent Developments/Updates
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Recombinant Insulin Lispro Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Pfizer Recombinant Insulin Lispro Injection Product
Table 94. Pfizer Recent Developments/Updates
Table 95. BI Corporation Information
Table 96. BI Description and Business Overview
Table 97. BI Recombinant Insulin Lispro Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. BI Recombinant Insulin Lispro Injection Product
Table 99. BI Recent Developments/Updates
Table 100. Sanofi Corporation Information
Table 101. Sanofi Description and Business Overview
Table 102. Sanofi Recombinant Insulin Lispro Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Sanofi Recombinant Insulin Lispro Injection Product
Table 104. Sanofi Recent Developments/Updates
Table 105. Takeda Pharmaceutical Company Corporation Information
Table 106. Takeda Pharmaceutical Company Description and Business Overview
Table 107. Takeda Pharmaceutical Company Recombinant Insulin Lispro Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Takeda Pharmaceutical Company Recombinant Insulin Lispro Injection Product
Table 109. Takeda Pharmaceutical Company Recent Developments/Updates
Table 110. Wanbang Biopharmaceuticals Corporation Information
Table 111. Wanbang Biopharmaceuticals Description and Business Overview
Table 112. Wanbang Biopharmaceuticals Recombinant Insulin Lispro Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Wanbang Biopharmaceuticals Recombinant Insulin Lispro Injection Product
Table 114. Wanbang Biopharmaceuticals Recent Developments/Updates
Table 115. United Laboratories Corporation Information
Table 116. United Laboratories Description and Business Overview
Table 117. United Laboratories Recombinant Insulin Lispro Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. United Laboratories Recombinant Insulin Lispro Injection Product
Table 119. United Laboratories Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Recombinant Insulin Lispro Injection Distributors List
Table 123. Recombinant Insulin Lispro Injection Customers List
Table 124. Recombinant Insulin Lispro Injection Market Trends
Table 125. Recombinant Insulin Lispro Injection Market Drivers
Table 126. Recombinant Insulin Lispro Injection Market Challenges
Table 127. Recombinant Insulin Lispro Injection Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Recombinant Insulin Lispro Injection
Figure 2. Global Recombinant Insulin Lispro Injection Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Recombinant Insulin Lispro Injection Market Share by Type in 2023 & 2030
Figure 4. 1ML Product Picture
Figure 5. 3ML Product Picture
Figure 6. 10ML Product Picture
Figure 7. Global Recombinant Insulin Lispro Injection Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Recombinant Insulin Lispro Injection Market Share by Application in 2023 & 2030
Figure 9. Hospital
Figure 10. Pharmacy
Figure 11. Global Recombinant Insulin Lispro Injection Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Recombinant Insulin Lispro Injection Market Size (2019-2030) & (US$ Million)
Figure 13. Global Recombinant Insulin Lispro Injection Sales (2019-2030) & (K Units)
Figure 14. Global Recombinant Insulin Lispro Injection Average Price (US$/Unit) & (2019-2030)
Figure 15. Recombinant Insulin Lispro Injection Report Years Considered
Figure 16. Recombinant Insulin Lispro Injection Sales Share by Manufacturers in 2023
Figure 17. Global Recombinant Insulin Lispro Injection Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Recombinant Insulin Lispro Injection Players: Market Share by Revenue in 2023
Figure 19. Recombinant Insulin Lispro Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Recombinant Insulin Lispro Injection Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Recombinant Insulin Lispro Injection Sales Market Share by Country (2019-2030)
Figure 22. North America Recombinant Insulin Lispro Injection Revenue Market Share by Country (2019-2030)
Figure 23. United States Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Recombinant Insulin Lispro Injection Sales Market Share by Country (2019-2030)
Figure 26. Europe Recombinant Insulin Lispro Injection Revenue Market Share by Country (2019-2030)
Figure 27. Germany Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Recombinant Insulin Lispro Injection Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Recombinant Insulin Lispro Injection Revenue Market Share by Region (2019-2030)
Figure 34. China Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Recombinant Insulin Lispro Injection Sales Market Share by Country (2019-2030)
Figure 44. Latin America Recombinant Insulin Lispro Injection Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Recombinant Insulin Lispro Injection Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Recombinant Insulin Lispro Injection Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Recombinant Insulin Lispro Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Recombinant Insulin Lispro Injection by Type (2019-2030)
Figure 54. Global Revenue Market Share of Recombinant Insulin Lispro Injection by Type (2019-2030)
Figure 55. Global Recombinant Insulin Lispro Injection Price (US$/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Recombinant Insulin Lispro Injection by Application (2019-2030)
Figure 57. Global Revenue Market Share of Recombinant Insulin Lispro Injection by Application (2019-2030)
Figure 58. Global Recombinant Insulin Lispro Injection Price (US$/Unit) by Application (2019-2030)
Figure 59. Recombinant Insulin Lispro Injection Value Chain
Figure 60. Recombinant Insulin Lispro Injection Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
